Top

Published in:

01-04-2017 | Clinical trial

Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients

Authors: Emerson A. Lim, Jacqueline E. Gunther, Hyun K. Kim, Molly Flexman, Hanina Hibshoosh, Katherine Crew, Bret Taback, Jessica Campbell, Kevin Kalinsky, Andreas Hielscher, Dawn L. Hershman

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Abstract

Purpose

Breast cancer (BC) patients who achieve a favorable residual cancer burden (RCB) after neoadjuvant chemotherapy (NACT) have an improved recurrence-free survival. Those who have an unfavorable RCB will have gone through months of ineffective chemotherapy. No ideal method exists to predict a favorable RCB early during NACT. Diffuse optical tomography (DOT) is a novel imaging modality that uses near-infrared light to assess hemoglobin concentrations within breast tumors. We hypothesized that the 2-week percent change in DOT-measured hemoglobin concentrations would associate with RCB.

Methods

We conducted an observational study of 40 women with stage II–IIIC BC who received standard NACT. DOT imaging was performed at baseline and 2 weeks after treatment initiation. We evaluated the associations between the RCB index (continuous measure), class (categorical 0, I, II, III), and response (RCB class 0/I = favorable, RCB class II/III = unfavorable) with changes in DOT-measured hemoglobin concentrations.

Results

The RCB index correlated significantly with the 2-week percent change in oxyhemoglobin [HbO₂] (r = 0.5, p = 0.003), deoxyhemoglobin [Hb] (r = 0.37, p = 0.03), and total hemoglobin concentrations [HbT] (r = 0.5, p = 0.003). The RCB class and response significantly associated with the 2-week percent change in [HbO₂] (p ≤ 0.01) and [HbT] (p ≤ 0.02). [HbT] 2-week percent change had sensitivity, specificity, positive, and negative predictive values for a favorable RCB response of 86.7, 68.4, 68.4, and 86.7%, respectively.

Conclusion

The 2-week percent change in DOT-measured hemoglobin concentrations was associated with the RCB index, class, and response. DOT may help guide NACT for women with BC.

Available only for authorised users

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685CrossRefPubMed

Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P et al (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A(5):645–652CrossRefPubMed

Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9(11):1179–1184CrossRefPubMed

Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10(1):47–52CrossRefPubMed

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422CrossRefPubMed

Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, Beyer T (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46(4):608–613PubMed

Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J (2010) Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Technol 38(1):6–17CrossRefPubMed

Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK et al (2006) Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257–264CrossRefPubMedPubMedCentral

Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92(3):231–238CrossRefPubMed

10.

Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH (2008) Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 10(10):1028–1040CrossRefPubMedPubMedCentral

11.

Flexman ML, Hernandez SL, Huang J, Johung TJ, Kim HK, Lee J, Vlachos F, Yamashiro DJ, Kandel J, Hielscher AH (2010) Early detection of tumor vascular response to anti-angiogenic drugs with optical tomography. Optical Society of America (OSA) topical meeting, Miami, Florida, 13 April 2010

12.

Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ (2007) Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci USA 104(10):4014–4019CrossRefPubMedPubMedCentral

13.

Soliman H, Gunasekara A, Rycroft M, Zubovits J, Dent R, Spayne J, Yaffe MJ, Czarnota GJ (2010) Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res 16(9):2605–2614CrossRefPubMed

14.

Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT, Zhang GQ, Pang D (2010) Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 136:1719–1727CrossRefPubMed

15.

Flexman ML, Khalil MA, Al Abdi R, Kim HK, Fong CJ, Desperito E, Hershman DL, Barbour RL, Hielscher AH (2011) Digital optical tomography system for dynamic breast imaging. J Biomed Opt 16(7):076014CrossRefPubMedPubMedCentral

16.

Zhu Q, Huang M, Chen N, Zarfos K, Jagjivan B, Kane M, Hedge P, Kurtzman SH (2003) Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. Neoplasia 5(5):379–388CrossRefPubMedPubMedCentral

17.

Zhu Q, Ricci A Jr, Hegde P, Kane M, Cronin E, Merkulov A, Xu Y, Tavakoli B, Tannenbaum S (2016) Assessment of functional differences in malignant and benign breast lesions and improvement of diagnostic accuracy by using US-guided diffuse optical tomography in conjunction with conventional US. Radiology. doi:10.1148/radiol.2016151097 PubMedCentral

18.

Ueda S, Nakamiya N, Matsuura K, Shigekawa T, Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Yamashita Y et al (2013) Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast. BMC Cancer 13:514CrossRefPubMedPubMedCentral

19.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA et al (2015) Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. Breast Cancer Res 17:72CrossRefPubMedPubMedCentral

20.

Kim MJ, Su MY, Yu HJ, Chen JH, Kim EK, Moon HJ, Choi JS (2016) US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers. BMC Cancer 16(1):50CrossRefPubMedPubMedCentral

21.

Xiao M, Jiang Y, Zhu Q, You S, Li J, Wang H, Lai X, Zhang J, Liu H, Zhang J (2015) Diffuse optical tomography of breast carcinoma: can tumor total hemoglobin concentration be considered as a new promising prognostic parameter of breast carcinoma? Acad Radiol 22(4):439–446CrossRefPubMed

22.

Ueda S, Yoshizawa N, Shigekawa T, Takeuchi H, Ogura H, Osaki A, Saeki T, Ueda Y, Yamane T, Kuji I et al (2016) Near-infrared diffuse optical imaging for early prediction of breast cancer response to neoadjuvant chemotherapy: a comparative study using FDG-PET/CT. J Nucl Med 57(8):1189–1195CrossRefPubMed

23.

Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, Forero JA, Muffly LS, Schwartz GN, Paulsen KD et al (2009) Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 252(2):551–560CrossRefPubMedPubMedCentral

24.

Jiang S, Pogue BW, Kaufman PA, Gui J, Jermyn M, Frazee TE, Poplack SP, DiFlorio-Alexander R, Wells WA, Paulsen KD (2014) Predicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatment. Clin Cancer Res 20(23):6006–6015CrossRefPubMedPubMedCentral

25.

Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, Xu S, O’Sullivan TD, Hsiang D, Mehta R et al (2012) Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res 72(17):4318–4328CrossRefPubMedPubMedCentral

26.

Xu C, Vavadi H, Merkulov A, Li H, Erfanzadeh M, Mostafa A, Gong Y, Salehi H, Tannenbaum S, Zhu Q (2016) Ultrasound-guided diffuse optical tomography for predicting and monitoring neoadjuvant chemotherapy of breast cancers: recent progress. Ultrason Imaging 38(1):5–18CrossRefPubMed

27.

Zhu Q, DeFusco PA, Ricci A Jr, Cronin EB, Hegde PU, Kane M, Tavakoli B, Xu Y, Hart J, Tannenbaum SH (2013) Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography. Radiology 266(2):433–442CrossRefPubMedPubMedCentral

28.

Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12(5):320–327CrossRefPubMed

29.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26(7):1280–1291PubMedPubMedCentral

30.

Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29(6):660–666CrossRefPubMed

Title: Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
Authors: Emerson A. Lim
Jacqueline E. Gunther
Hyun K. Kim
Molly Flexman
Hanina Hibshoosh
Katherine Crew
Bret Taback
Jessica Campbell
Kevin Kalinsky
Andreas Hielscher
Dawn L. Hershman
Publication date: 01-04-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4150-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial

Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells

Role of HYAL1 expression in primary breast cancer in the formation of brain metastases

Aspirin use is associated with lower mammographic density in a large screening cohort

Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors

MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer